*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Stomach-specific planning and analysis of sustained release floating in-situ gelling method for the distribution of anti-ulcer medication.

Author: VIJAYSINH SABLE, MAHESH K. GUPTA, NEETESH K. JAIN, GURDEEP SINGH
Abstract: Gastroretentive drug delivery is one of the main methods for prolonging gastric occupancy, peptic ulcer control and site-specific medication release enhancement for local or systemic effects in the upper gastrointestinal tract (GIT). Several approaches for the distribution of gastroretentive drugs have been planned and developed over the last few decades. We also developed oral sustained release in-situ floating gel as a carrier for the transmission of anti-nizatidine (NZD) unique to the stomach in present work. NZD is histamine H2-receptor antagonist. This is usually seen in extreme duodenal ulcers, stomach ulcers, heartburn, ulcerative esophagitis. Nonetheless, the recent inability of proton pump inhibitors to counteract the increase in gastric acid at night (related to elevated production in histamine at night) and side effects from certain H2 receptor antagonists (gyanacomastia) open up a different route to NZD transmission at particular periods in relation to the initiation of symptoms. Approximately 10 lots (F1-F10) were formulated and subjected to determination of f2 performance, viscosity (cps), gel strength (dyne / cm2), pH, product quality, and pharmacokinetic in vivo research. In-vivo experiments revealed a significant difference in the reduction of the ulcer index and the amount of gastric acid secretion from the formulation of nizatidine in situ gelling (for optimized batch F6) relative to the nizatidine solution (P < 0.01) and control group (P < 0.001). As a result, an efficient oral sustained release in-situ floating gel was developed and tested effectively as a carrier for stomach-specific distribution of anti Nizatidine.
Keyword: Nizatidine, Gellan gum, Oral Sustained Release, In-Situ Floating Gel.
DOI: https://doi.org/10.31838/ijpr/2020.12.03.130
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free